Document Detail


Androgen excess in women: experience with over 1000 consecutive patients.
MedLine Citation:
PMID:  14764747     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The objective of the present study was to estimate the prevalence of the different pathological conditions causing clinically evident androgen excess and to document the degree of long-term success of suppressive and/or antiandrogen hormonal therapy in a large consecutive population of patients. All patients presenting for evaluation of symptoms potentially related to androgen excess between October 1987 and June 2002 were evaluated, and the data were maintained prospectively in a computerized database. For the assessment of therapeutic response, a retrospective review of the medical chart was performed, after the exclusion of those patients seeking fertility therapy only, or with inadequate follow-up or poor compliance. A total of 1281 consecutive patients were seen during the study period. Excluded from analysis were 408 patients in whom we were unable to evaluate hormonal status, determine ovulatory status, or find any evidence of androgen excess. In the remaining population of 873 patients, the unbiased prevalence of androgen-secreting neoplasms was 0.2%, 21-hydroxylase-deficient classic adrenal hyperplasia (CAH) was 0.6%, 21-hydroxylase-deficient nonclassic adrenal hyperplasia (NCAH) was 1.6%, hyperandrogenic insulin-resistant acanthosis nigricans (HAIRAN) syndrome was 3.1%, idiopathic hirsutism was 4.7%, and polycystic ovary syndrome (PCOS) was 82.0%. Fifty-nine (6.75%) patients had elevated androgen levels and hirsutism but normal ovulation. A total of 257 patients were included in the assessment of the response to hormonal therapy. The mean duration of follow-up was 33.5 months (range, 6-155). Hirsutism improved in 86%, menstrual dysfunction in 80%, acne in 81%, and hair loss in 33% of patients. The major side effects noted were irregular vaginal bleeding (16.1%), nausea (13.0%), and headaches (12.6%); only 36.6% of patients never complained of side effects. In this large study of consecutive patients presenting with clinically evident androgen excess, specific identifiable disorders (NCAH, CAH, HAIRAN syndrome, and androgen-secreting neoplasms) were observed in approximately 7% of subjects, whereas functional androgen excess, principally PCOS, was observed in the remainder. Hirsutism, menstrual dysfunction, or acne, but not alopecia, improved in the majority of patients treated with a combination suppressive therapy; although more than 60% experienced side effects.
Authors:
R Azziz; L A Sanchez; E S Knochenhauer; C Moran; J Lazenby; K C Stephens; K Taylor; L R Boots
Related Documents :
934557 - Selection of patients for clomiphene citrate therapy.
20205117 - Congenital adrenal hyperplasia due to 21-hydroxylase deficiency - management in adults.
22672187 - Synergistic impact of low serum albumin on intensive care unit admission and high blood...
9255217 - The not-so-good old days: working with pituitary growth hormone in north america, 1956 ...
21556777 - Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthrit...
6802307 - Shortening waiting lists in orthopaedic surgery outpatient clinics.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  89     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  2004 Feb 
Date Detail:
Created Date:  2004-02-06     Completed Date:  2004-03-26     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  453-62     Citation Subset:  AIM; IM    
Affiliation:
Departments of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama 35233, USA. azzizr@cshs.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acanthosis Nigricans / complications*,  epidemiology
Adrenal Hyperplasia, Congenital / complications*,  epidemiology
Adult
Androgen Antagonists / adverse effects,  therapeutic use
Androgens / secretion*
Endocrine Gland Neoplasms / complications*,  epidemiology,  secretion*
Female
Humans
Hyperandrogenism / drug therapy,  etiology*
Prevalence
Retrospective Studies
Time Factors
Treatment Outcome
Grant Support
ID/Acronym/Agency:
K24-DK01346/DK/NIDDK NIH HHS; R01-HD29364/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
0/Androgen Antagonists; 0/Androgens

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimenta...
Next Document:  Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients ...